ArticleOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2026
Rate of Hearing Loss in Platinum-Naïve Patients Receiving Immune Checkpoint Inhibitors.
Article in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHearing loss from immune checkpoint inhibitors (ICIs) has been documented in case reports and case series. We present the largest retrospective study investigating the rate of ICI-related ototoxicity in a monitored cohort of platinum-naïve patients. STUDY
designRetrospective cohort study.
settingTertiary-care center.
methodsPatients treated with ICI between January 1, 2017, and December 31, 2022, with baseline and post-treatment audiograms, were included. Patients with a history of platinum-based chemotherapy were excluded. Demographics, oncologic diagnosis, ICI treatment details, and temporal bone irradiation (TBRT) were recorded. Audiometric thresholds were compared before and after ICI therapy. The primary outcome measure was a change in hearing as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). Secondary outcome measures included changes in hearing using the American Speech-Language-Hearing Association (ASHA) and TUNE criteria.
resultsAmong 15,390 ICI recipients, 29 platinum-naïve patients met the inclusion criteria. Six of 29 patients (20.7%) experienced a CTCAE grade 1 or higher hearing loss. The proportions of hearing loss as defined by ASHA and TUNE criteria were 44.8% and 27.6%, respectively. The length of time between baseline and follow-up audiograms was significantly longer among patients with hearing loss (mean difference [days]: CTCAE: 590.3, P < .01; ASHA: 280.9, P = .05; and TUNE: 122.1, P = .46). No other potential covariates believed to be confounders were significantly associated with the outcome.
conclusionA significant proportion of our monitored platinum-naïve ICI patients met hearing-loss criteria. Prospective studies with standardized audiologic surveillance are needed to further quantify the true incidence of ICI ototoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.